Literature DB >> 29212356

Does the total dysphagia risk score correlate with swallowing function examined by videofluoroscopy?

Daan Nevens1, Ann Goeleven2, Fréderic Duprez3, R Braeken4, E Decabooter4, M De Smet4, L Lutters4, Eddy Dejaeger5, Wilfried De Neve3, Sandra Nuyts1.   

Abstract

OBJECTIVE: The purpose of this study was to correlate the total dysphagia risk score (TDRS) with swallowing function as measured by videofluoroscopy of swallowing using the swallowing performance scale (SPS) and the penetration aspiration scale (PAS).
METHODS: 63 patients from two different centres treated with radiotherapy for head and neck cancer were evaluated in the current study. Swallowing videofluoroscopies at baseline, 6 and 12 months following radiotherapy were evaluated by two observers. The TDRS of all patients was calculated and correlated with the consensus PAS and SPS scores of the two observers.
RESULTS: Regarding the PAS scale, we did not observe a significant correlation with the TDRS. Regarding SPS, we found a significant correlation at 6 months (p = 0.01) and a borderline significant correlation at 12 months (p = 0.05). We observed statistically lower SPS scores for patients in the intermediate-risk category when compared to the high-risk category. When we compared low vs high TDRS risk patients, we did not observe a significant difference regarding SPS scores. When comparing low- vs intermediate-risk patients, we observed higher SPS scores in the low-risk group (p = 0.01). When the low- and intermediate-risk patients were grouped together, we observed less swallowing problems as measured by SPS in the low and intermediate group when compared to the high-risk group (p = 0.05) at 6 months.
CONCLUSION: Patients with high-risk TDRS scores have higher SPS scores when compared to the intermediate group and the intermediate- and low-risk group together. However, low-risk patients in our patient cohort could not be distinguished from high or intermediate-risk patients. Advances in knowledge: TDRS was never correlated with videofluoroscopies in past studies. The hypothesis of this paper was to see if the TDRS could guide us to see which patients are at risk for high scores on SPS and PAS and might need a videofluoroscopic examination in the follow up. Given the poor correlations in our study, however, we cannot recommend the use of the TDRS to select patients who might benefit from the additional information provided by videofluoroscopies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29212356      PMCID: PMC5965465          DOI: 10.1259/bjr.20170714

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

1.  Interjudge and intrajudge reliabilities in fiberoptic endoscopic evaluation of swallowing (fees) using the penetration-aspiration scale: a replication study.

Authors:  Nancy Colodny
Journal:  Dysphagia       Date:  2002       Impact factor: 3.438

2.  Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially accelerated radiotherapy scheme.

Authors:  Daan Nevens; Sarah Deschuymer; Johannes A Langendijk; Jean-François Daisne; Fréderic Duprez; Wilfried De Neve; Sandra Nuyts
Journal:  Radiother Oncol       Date:  2015-10-20       Impact factor: 6.280

3.  Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity.

Authors:  Sandra Nuyts; Maarten Lambrecht; Fréderic Duprez; Jean-Francois Daisne; Dirk Van Gestel; Danielle Van den Weyngaert; Nele Platteaux; Yasmyne Geussens; Mia Voordeckers; Indira Madani; Wilfried De Neve
Journal:  Radiother Oncol       Date:  2013-08-13       Impact factor: 6.280

4.  A penetration-aspiration scale.

Authors:  J C Rosenbek; J A Robbins; E B Roecker; J L Coyle; J L Wood
Journal:  Dysphagia       Date:  1996       Impact factor: 3.438

5.  Objective assessment of swallowing function after definitive concurrent (chemo)radiotherapy in patients with head and neck cancer.

Authors:  Jaiprakash Agarwal; Vijay Palwe; Debnarayan Dutta; Tejpal Gupta; Sarbani Ghosh Laskar; Ashwini Budrukkar; Vedang Murthy; Pankaj Chaturvedi; Prathamesh Pai; Devendra Chaukar; Anil K D'Cruz; Suyash Kulkarni; Aniruddha Kulkarni; Gurmit Baccher; Shyam Kishore Shrivastava
Journal:  Dysphagia       Date:  2011-02-23       Impact factor: 3.438

6.  Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.

Authors:  Keiichiro Koiwai; Naoto Shikama; Shigeru Sasaki; Atsunori Shinoda; Masumi Kadoya
Journal:  Radiother Oncol       Date:  2010-10       Impact factor: 6.280

7.  The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study.

Authors:  Irma M Verdonck-de Leeuw; Laurien M Buffart; Martijn W Heymans; Derek H Rietveld; Patricia Doornaert; Remco de Bree; Jan Buter; Neil K Aaronson; Ben J Slotman; C René Leemans; Johannes A Langendijk
Journal:  Radiother Oncol       Date:  2014-02-25       Impact factor: 6.280

8.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

Review 9.  Dysphagia in head and neck cancer patients treated with chemoradiotherapy.

Authors:  Nele Platteaux; Piet Dirix; Eddy Dejaeger; Sandra Nuyts
Journal:  Dysphagia       Date:  2009-08-27       Impact factor: 3.438

Review 10.  Swallowing dysfunction in cancer patients.

Authors:  Judith E Raber-Durlacher; Mike T Brennan; Irma M Verdonck-de Leeuw; Rachel J Gibson; June G Eilers; Tuomas Waltimo; Casper P Bots; Marisol Michelet; Thomas P Sollecito; Tanya S Rouleau; Aniel Sewnaik; Rene-Jean Bensadoun; Monica C Fliedner; Sol Silverman; Fred K L Spijkervet
Journal:  Support Care Cancer       Date:  2011-12-29       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.